At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 176 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Apremilast (AMG 407) in Japanese Subjects With Palmoplantar Pustulosis (PPP)
In Brief
A Phase 3 clinical trial evaluating Apremilast and Placebo for Palmoplantar Pustulosis. Completed, enrolled 176 participants across 40 sites.
Detailed Summary
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPalmoplantar Pustulosis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartMar 2022
Primary CompletionAug 2023
Study CompletionJun 2024
TodayJul 2026
First PostedDec 30, 2021
Enrollment StartMar 8, 2022
Primary CompletionAug 19, 2023
Study CompletionJun 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.5 years ago
Interventions
Apremilastdrug
Oral tablets
Placebodrug
Oral tablets